Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study

Patients with relapsed malignant glioma have a poor prognosis. We developed a strategy of vaccination using autologous mature dendritic cells loaded with autologous tumour homogenate. In total, 12 patients with a median age of 36 years (range: 11–78) were treated. All had relapsing malignant glioma....

Descripción completa

Detalles Bibliográficos
Autores principales: Rutkowski, S, De Vleeschouwer, S, Kaempgen, E, Wolff, J E A, Kühl, J, Demaerel, P, Warmuth-Metz, M, Flamen, P, Van Calenbergh, F, Plets, C, Sörensen, N, Opitz, A, Van Gool, S W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409960/
https://www.ncbi.nlm.nih.gov/pubmed/15477864
http://dx.doi.org/10.1038/sj.bjc.6602195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409960/
https://www.ncbi.nlm.nih.gov/pubmed/15477864
http://dx.doi.org/10.1038/sj.bjc.6602195

Ejemplares similares